Royce & Associates LP Raises Stake in Establishment Labs Holdings Inc. $ESTA

Royce & Associates LP increased its stake in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 24.2% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 358,541 shares of the company’s stock after purchasing an additional 69,766 shares during the period. Royce & Associates LP owned 1.23% of Establishment Labs worth $26,130,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in ESTA. Quarry LP purchased a new stake in Establishment Labs during the 3rd quarter worth about $34,000. State of Wyoming purchased a new stake in Establishment Labs during the 3rd quarter worth about $71,000. Osaic Holdings Inc. lifted its holdings in Establishment Labs by 900.0% during the 2nd quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after purchasing an additional 1,800 shares in the last quarter. Truist Financial Corp purchased a new stake in Establishment Labs during the 4th quarter worth about $200,000. Finally, PharVision Advisers LLC purchased a new stake in Establishment Labs during the 3rd quarter worth about $203,000. Hedge funds and other institutional investors own 72.91% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on ESTA. Needham & Company LLC raised their price target on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, February 24th. BTIG Research raised their price target on Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Stephens raised their price target on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a report on Wednesday, May 6th. Finally, Mizuho raised their price target on Establishment Labs from $90.00 to $100.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $87.14.

Establishment Labs Stock Performance

NASDAQ:ESTA opened at $72.64 on Wednesday. The business’s 50-day moving average price is $64.95 and its two-hundred day moving average price is $68.33. Establishment Labs Holdings Inc. has a twelve month low of $33.35 and a twelve month high of $83.31. The stock has a market cap of $2.14 billion, a P/E ratio of -48.75 and a beta of 1.12. The company has a quick ratio of 1.91, a current ratio of 2.96 and a debt-to-equity ratio of 16.82.

Establishment Labs (NASDAQ:ESTA) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.10). The business had revenue of $59.88 million during the quarter, compared to analysts’ expectations of $57.40 million. Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business’s revenue was up 44.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.70) EPS. As a group, equities analysts predict that Establishment Labs Holdings Inc. will post -1.07 EPS for the current fiscal year.

Insider Buying and Selling at Establishment Labs

In related news, Director Quiros Juan Jose Chacon sold 105,000 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The stock was sold at an average price of $75.42, for a total transaction of $7,919,100.00. Following the transaction, the director directly owned 927,504 shares of the company’s stock, valued at approximately $69,952,351.68. This trade represents a 10.17% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 330,000 shares of company stock worth $22,854,538. Company insiders own 9.99% of the company’s stock.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.